quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation

View original at globenewswire.com
Cibus Names Agricultural Biotechnology Leader Craig Wichner as Chief Executive Officer to Accelerate Growth and Value Creation SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Peter Beetham shepherded the company to the precipice of its initial commercialization targets while raising over $62 million in new investment during his 15-month interim CEO tenure

    60% confidence
  • Craig Wichner has been a recognized leader in demonstrating how regenerative and organic farming practices can drive both strong financial performance and measurable environmental outcomes

    60% confidence
  • Cibus is not a seed company; it is a technology company that uses gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and licenses them to customers in exchange for royalties

    60% confidence
  • RTDS and the Trait Machine process represent the technological breakthrough in plant breeding that is the ultimate promise of plant gene editing: high-throughput gene editing systems operating as an extension of seed company breeding programs

    60% confidence
  • Cibus is at a pivotal moment and Craig Wichner is the right leader for the next phase of growth

    60% confidence
  • Cibus has breakthrough technology and a clear path to commercialization; Wichner's immediate focus is execution, converting near-term commercialization targets into revenue with capital discipline

    60% confidence
  • Craig Wichner has an exceptional combination of financial acumen, strategic discipline, and industry insight and leadership, with a proven track record of delivering results and creating value

    60% confidence
  • Craig Wichner's experience will be invaluable as Cibus executes its capital strategy to drive longer-term value creation through realization of its vision for the future of agriculture

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com